Implant Sciences Corporation (OTCQB:IMSC) has deployed QS-B220 desktop explosives and drugs trace detectors (ETD) to more than 160 airports across the US and Europe in the past 12 months, the company said.
Implant Sciences won the 1,170 unit order from the US Transportation Security Administration (TSA) in November, 2014. These units, which began shipping in December 2015, are continuing to be deployed across nearly 200 United States airports. Implant Sciences also announced the capture of the 122 unit order from the Canadian Air Transport Security Authority (CATSA) in January, 2016. Those units are also currently being deployed to airports across Canada.
Over 1,000 units were sold to support ECAC demand to European airports in 14 countries, and substantial follow-on orders continue to be in play in the region.
The QS-B220 uses ion mobility spectrometry (IMS) to detect and identify trace amounts of a wide variety of military, commercial and homemade explosives. The device features a radioactive material-free design, push-button maintenance and diagnostics and a patented inCal internal automatic calibration system.
Implant Sciences develops and manufactures advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The company has developed proprietary technologies used in its commercial products.